Patrick J Heron has bought stock on 18 days since Feb 2020
Director at Mirum Pharmaceuticals, Inc., and 3 other companies
SEC CIK 0001365617 · Filings on SEC.gov ↗
Patrick J Heron's record
3 months after each buy, from the first price a copier could get.
16 buys since 2020 with 3 months of prices.
Companies
Every filing
18 filings since Feb 2020, newest first
Mirum Pharmaceuticals, Inc.
Director
Mbx Biosciences, Inc.
Director and 10% owner
Arcutis Biotherapeutics, Inc.
Director
Arcutis Biotherapeutics, Inc.
Director
Arcutis Biotherapeutics, Inc.
Director
Arcutis Biotherapeutics, Inc.
Director
Arcutis Biotherapeutics, Inc.
Director
Arcutis Biotherapeutics, Inc.
Director
Mirum Pharmaceuticals, Inc.
Director
Mirum Pharmaceuticals, Inc.
Director
Mirum Pharmaceuticals, Inc.
Director
Mbx Biosciences, Inc.
Director and 10% owner
Arcutis Biotherapeutics, Inc.
Director
Mirum Pharmaceuticals, Inc.
Director
Mirum Pharmaceuticals, Inc.
Director
Mirum Pharmaceuticals, Inc.
Director and 10% owner
Passage Bio, Inc.
Director and 10% owner
Arcutis Biotherapeutics, Inc.
Director and 10% owner
About Patrick J Heron
Patrick J. Heron is a seasoned life sciences investor and Managing General Partner at Frazier Life Sciences since 1999, where he has led or co-led investments in over 30 companies, including successful exits like ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), and Silvergate Pharmaceuticals (acquired by CutisPharma).( Prior to Frazier, he developed McKinsey & Company's West Coast biotechnology consulting practice, focusing on mergers, acquisitions, product launches, and research prioritization; he holds a B.A. in Political Science from the University of North Carolina at Chapel Hill (Phi Beta Kappa, Morehead Scholar) and an M.B.A. from Harvard Business School.(
Heron serves as a director at MBX Biosciences, Inc. (MBX), where he is designated as Director, 10% Owner, holding approximately 5,219,440 shares, and recently purchased $10 million in IPO shares.( He is also a Class III independent director and Compensation Committee member at Arcutis Biotherapeutics (ARQT) since 2016, having chaired the board from 2019 to November 2024, and holds directorships at Mirum Pharmaceuticals, HilleVax, and Scout Bio, among others.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.